Pfizer plans fight to hold share against generic cholesterol drugs

10/17/2005 | NYTimes.com

Insurers and government agencies look forward to billions of dollars in savings when they can move patients from Pfizer's cholesterol drug Lipitor to less expensive generics such as Merck's Zocor and newer generics expected to hit the market. Merck's patent on Zocor expires in June; Pfizer plans to fight the migration to generic versions of Zocor by using its marketing muscle and clinical data showing Lipitor is more effective than the generics.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC